News

Virginia Tech joins with universities, bioscience companies to address health care needs

With funding from Virginia Catalyst, also known as the Virginia Biosciences Health Research Corp., Virginia Tech is engaged in three collaborative bioscience projects to address unmet health care needs in Virginia, according to Michael Friedlander, vice president for health sciences and technology at Virginia Tech.

The Catalyst awards, which range from $350,000 to $800,000, support joint research projects between industry and Virginia universities that have the potential to significantly improve human health and create high value jobs in the commonwealth.

“All three projects are related to biomedical research and development,” said Friedlander, who is also the executive director of the Fralin Biomedical Research Institute at VTC. “Each project tackles a different aspect of medical science, including RNA-based precision medicine for lupus disease management, treatment of high-dose ionizing radiation, and a hybrid alpha-pseudovirus platform to develop the next generation of vaccines.”

Virginia Tech will collaborate with the University of Virginia on two of the three projects and with George Mason University on the third project.

“We are excited to continue our mission of supporting collaborations and fostering economic growth in Virginia’s life sciences, enabling the commonwealth to compete on a national and global scale,” Mike Grisham, CEO of Virginia Catalyst, said in a news release. “The critical mass achieved by these collaborations provides Virginia with competitive advantages over other states and has resulted in significant outside capital being invested to finance the commercialization of Virginia’s innovations and create significant high-paying jobs for the commonwealth.”

The projects include

  • A hybrid alpha-pseudovirus, multi-viral nasal vaccine platform
    Company: Virongy Biosciences, Manassas
    University collaborators: George Mason University and Virginia Tech, Kylene Kehn-Hall, professor, biomedical sciences and pathobiology, Virginia-Maryland College of Veterinary Medicine
    Funding amount: $500,000
  • A novel platform for treatment of high dose Iionizing radiation
    Company: The Tiny Cargo Co., a Roanoke-based spinoff of the Fralin Biomedical Research Institute with postdoctoral associate and Chief Scientific Officer Spencer Marsh
    University collaborators: University of Virginia and Virginia Tech, Marsh and Rob Gourdie, professor,  Fralin Biomedical Research Institute
    Funding amount: $350,000
  • RNA based precision medicine for lupus disease management
    Company: AMPEL BioSolutions LLC, Charlottesville
    University collaborators: University of Virginia and Virginia Tech, Xin Luo, associate professor, Chris Reilly, adjunct research associate professor, biomedical sciences and pathobiology, Virginia-Maryland College of Veterinary Medicine
    Funding amount: $800,000

Recent News

09/22/2023

State public health laboratory, Henrico County Schools launch pilot program to promote life science career

More than 50 Henrico County high school students and teachers joined scientists from Virginia’s public health and environmental laboratory Wednesday to kick off an innovative program that brings together private and government scientists and experts, business and nonprofit leaders, and public schools to explore ways to create a pipeline of talent to fuel Virginia’s growing

09/21/2023

Climate Tech Startup ThermaGEL Innovations’ Breakthrough Aerogels Join the Challenge to Save Half-Gigaton of C02 Emissions Each Year

In the fight against climate change, properly insulating homes and buildings can significantly raise energy efficiency and indoor air quality while lowering carbon dioxide emissions. A startup company, spun out of research at Virginia Commonwealth University, is commercializing what it calls a breakthrough in low-cost insulation materials. ThermaGEL Innovations has developed insulation material using aerogels,

09/20/2023

Charlottesville healthy sugar innovator Bonumose raises $2M

Bonumose Inc., a Charlottesville startup specializing in table sugar alternatives, has raised $2 million toward a $10 million funding round after German flavor and fragrances producer Symrise AG signed a minority investment agreement with the company. “The strategic investment from Symrise is part of a larger funding round that will be used for increasing sales,